Journals / Turkish Journal of Internal Medicine / 2022 / Supplement 1

Radiotherapy could increase the efficacy of immunotherapy in non-small cell lung cancer

Pages
71–80
Publication Date
2022-04-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Median progression-free survival (PFS) was 4.4 months (95% CI; 3.2-5.6), and median overall survival (OS) was 16.4 months (95% CI; 5.6-27.3). 14 (56%) of the patients had received RT.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: In non-small cell lung cancer (NSCLC), immunotherapy is a treatment option in patients without targetable mutations in second and later lines.
📊
Key Findings & Data:Results: The median age of the patients was 61.7 (26.6-81.2) years. 19 (76%) patients were male. 11 (44%) of the patients had received immunotherapy in the second-line and 14 (66%) in ≥3 lines.
💡
Conclusion & Impact:Median progression-free survival (PFS) was 4.4 months (95% CI; 3.2-5.6), and median overall survival (OS) was 16.4 months (95% CI; 5.6-27.3). 14 (56%) of the patients had received RT.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Immunotherapy · radiotherapy · efficacy

Abstract

Background: In non-small cell lung cancer (NSCLC), immunotherapy is a treatment option in patients without targetable mutations in second and later lines. Nevertheless, there is no validated test that can predict immunotherapy response. Material and Methods: Our study aimed to investigate the effect of radiotherapy (RT) on survival in patients with NSCLC receiving immunotherapy after first-line chemotherapy. Twenty-five patients diagnosed with NSCLC and received immunotherapy after at least one previous chemotherapy line were included in our study. Results: The median age of the patients was 61.7 (26.6-81.2) years. 19 (76%) patients were male. 11 (44%) of the patients had received immunotherapy in the second-line and 14 (66%) in ≥3 lines. Patients had received a median of 5 cycles (1-27) of immunotherapy. RT to immunotherapy interval was 6.4 months (1.0-11.8). Partial response was observed in 12 patients, stable disease in 8 patients, progression in 1 patient, and hyperprogression in 4 patients. Median progression-free survival (PFS) was 4.4 months (95% CI; 3.2-5.6), and median overall survival (OS) was 16.4 months (95% CI; 5.6-27.3). 14 (56%) of the patients had received RT. RT was administered to 12 patients before immunotherapy, and two patients received RT to bones during immunotherapy. The patients who received RT had statistically longer PFS (4.9 vs 3.9 months, p=0.012) and OS (18.7 vs 7.3 months, p=0.023) comparing those without RT. Conclusions: Our findings showed that RT significantly improved the survival in patients who received immunotherapy, pointing that RT may have an influential role in immunotherapy response.

🔖

Cite This Article

OCAK, B., SARIHAN, S., ŞAHİN, A. B., DAKİKİ, B., CANER, B., GÜLŞEN, K., TANRIVERDİ, Ö., DELİGÖNÜL, A., ÇUBUKÇU, E., EVRENSEL, T. (2022). Radiotherapy could increase the efficacy of immunotherapy in non-small cell lung cancer. Turkish Journal of Internal Medicine, Supplement 1, 71–80. https://ajindex.com/articles/808983

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424. doi: 10.3322/ caac.21492. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non- small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584-94. doi: 10.4065/83.5.584. National Comprehensive Cancer Network. Non–small cell lung cancer (Version 5.2021). Available at: https://www.nccn.org/ professionals/physician_gls/pdf/nscl.pdf. Accessed June 20, 2021.
  2. Wang C, Thudium KB, Han M, Wang XT, Huang H,Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, Singh S, Wong S, Garner N, Leblanc H, Bunch RT, Blanset D, Selby MJ, Korman AJ. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non- human primates. Cancer Immunol Res. 2014;2:846-56. doi: 10.1158/2326-6066.CIR-14-0040.
  3. Fessas P, Lee H, Ikemizu S, Janowitz T. A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol. 2017;44:136-40. doi: 10.1053/j.seminoncol.2017.06.002. Chen DS, Irving BA, Hodi FS. Molecular pathways: next- generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18:6580-7. doi: 10.1158/1078-0432.CCR-12-1362.
  4. Gettinger S, Herbst RS. B7-H1/PD-1 blockade therapy in non– small cell lung cancer: current status and future direction. Cancer J. 2014;20:281-9. doi: 10.1097/PPO.0000000000000063. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH,, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatiaet S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-65. doi: 10.1056/ NEJMoa1200694. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-54. doi: 10.1056/ NEJMoa1200690. Herb